GLOBAL MAPPING OF HEPATITIS B
| Friday, 7th of August 2015 |
 |
 |
GLOBAL MAPPING OF HEPATITIS B
Hep B is one of the two vaccines (HPV being the other) which prevent cancer (liver cancer and cervical cancer respectively). However, the benefits of the jab are not instantly apparent, because the latent period for development of the disease is years and, quite often, decades after infection.
http://www.cdc.gov/globalhealth/immunization/othervpds/preventing_hepatitisb.html
This prevalence map is a bit misleading, because it suggests that sub-Saharan Africa is lagging. In point of fact, infant administration of hep B vaccine is part of the schedule in all of those countries with high seroprevalence in the general population. That high seroprevalence will only come down over decades.
Hep B, with its carrier state, cannot be eliminated in the general population by mass campaigns. However, prevalence may be declining so fast in East Asia and sub-Saharan Africa that the world will be within shooting distance of global eradication by mid-century.
| Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
| Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
| Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
| Immunization Agenda 2030
Tuesday, 11th of February 2020 |
 |
41193495 |
| www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |